Novartis
NEWS
Typically, fewer than half of kidney transplants last 10 years. As a result, durability is definitely a significant unmet need for patients who have had a transplant or are waiting to receive one.
Companies share robust oncology data at annual ASCO meeting.
Overall survival rates in the intent-to-treat population at 42 months for the Kisquali combination group was 70.2% compared to 46.0% for hormone therapy alone.
Although the weekend was filled with news out of the American Society of Clinical Oncology Annual Meeting, here’s a roundup of some of the top clinical trial news from earlier last week.
Novartis’s QMF149 met its primary and key secondary endpoints in the Phase III QUARTZ clinical trial for asthma. QMF149 is a once-daily, fixed-dose combination therapy containing indacaterol acetate, a long-acting beta agonist, and mometasone furoate, an anti-inflammatory.
With ASCO set to kick off on Friday, companies prepare to share data from multiple cancer treatment pipeline programs.
The approval of Piqray combined with fulvestrant is the first FDA-approved treatment for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancer.
The price of the one-and-done gene therapy treatment is about half of what was initially projected by Novartis.
Investors and analysts get a close-up look at the Swiss pharma giant’s pipeline and growth strategies.
JOBS
IN THE PRESS